Cellular Responses to p53 Activation by Nutlin-3a

Nutlin-3a 激活 p53 的细胞反应

基本信息

  • 批准号:
    8471662
  • 负责人:
  • 金额:
    $ 28.38万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-07-13 至 2015-05-31
  • 项目状态:
    已结题

项目摘要

Project Summary / Abstract: Wild-type p53 is a potent tumor suppressor that is activated by DNA damage and other stresses. There has been considerable interest in restoring wild-type p53 function as a therapeutic strategy. This goal has led to the development of the Nutlin-3 (Nutlin), a small molecule that activates wild-type p53 by blocking its interaction with MDM2, the primary negative regulator of p53 activity in cells. Notably, Nutlin activates p53 through a non-genotoxic mechanism, and thus its use as a therapeutic agent may spare tissues of deleterious side-effects associated with common DNA damaging drugs. Effective use of Nutlin requires that its effects on cells be fully understood. We have examined the response of various p53 wild-type cell lines to transient Nutlin treatment. We find that p53 activation by Nutlin can promote growth arrest or apoptosis in cells dependent on activation of survival pathways, and we have identified a candidate survival factor that protects cells from Nutlin-induced apoptosis. We also find that Nutlin has surprising effects on cytoskeletal organization and control of DNA endoreduplication. The purpose of this grant is to determine the effects of Nutlin-mediated p53 activation on these various cellular responses.
项目概要/摘要: 野生型p53是一种有效的肿瘤抑制因子,可被DNA损伤和其他应激激活。一直 作为一种治疗策略,恢复野生型p53的功能一直受到相当大的关注。这一目标导致 Nutlin-3(Nutlin)是一种通过阻断野生型p53的表达来激活野生型p53的小分子, MDM 2是细胞中p53活性的主要负调节因子。值得注意的是,Nutlin激活p53 通过非遗传毒性机制,因此其作为治疗剂的用途可以使组织免于有害的 与常见的DNA损伤药物相关的副作用。有效使用Nutlin要求其对 细胞被完全理解。我们已经研究了各种p53野生型细胞系对短暂的 Nutlin治疗。我们发现Nutlin激活p53可以促进细胞生长停滞或凋亡 依赖于生存途径的激活,我们已经确定了一个候选生存因素,可以保护 Nutlin诱导的细胞凋亡。我们还发现Nutlin对细胞骨架组织有惊人的影响 和控制DNA核内复制。该补助金的目的是确定Nutlin介导的 p53激活对这些不同的细胞反应的影响。

项目成果

期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Pharmacologic activation of p53 by small-molecule MDM2 antagonists.
  • DOI:
    10.2174/138161211795222603
  • 发表时间:
    2011
  • 期刊:
  • 影响因子:
    3.1
  • 作者:
    Shen H;Maki CG
  • 通讯作者:
    Maki CG
Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3.
  • DOI:
    10.1038/onc.2011.185
  • 发表时间:
    2011-11-17
  • 期刊:
  • 影响因子:
    8
  • 作者:
    Aziz, M. H.;Shen, H.;Maki, C. G.
  • 通讯作者:
    Maki, C. G.
p53-regulated autophagy is controlled by glycolysis and determines cell fate.
  • DOI:
    10.18632/oncotarget.5218
  • 发表时间:
    2015-09-15
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Duan L;Perez RE;Davaadelger B;Dedkova EN;Blatter LA;Maki CG
  • 通讯作者:
    Maki CG
Critical roles for nitric oxide and ERK in the completion of prosurvival autophagy in 4OHTAM-treated estrogen receptor-positive breast cancer cells.
  • DOI:
    10.1016/j.canlet.2014.07.031
  • 发表时间:
    2014-10-28
  • 期刊:
  • 影响因子:
    9.7
  • 作者:
    Duan L;Danzer B;Levenson VV;Maki CG
  • 通讯作者:
    Maki CG
Two 4N cell-cycle arrests contribute to cisplatin-resistance.
  • DOI:
    10.1371/journal.pone.0059848
  • 发表时间:
    2013
  • 期刊:
  • 影响因子:
    3.7
  • 作者:
    Shen H;Perez RE;Davaadelger B;Maki CG
  • 通讯作者:
    Maki CG
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Carl G Maki其他文献

Carl G Maki的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Carl G Maki', 18)}}的其他基金

A synthetic lethal approach for targeting p53 deficient triple negative breast cancer
针对 p53 缺陷三阴性乳腺癌的合成致死方法
  • 批准号:
    10650026
  • 财政年份:
    2023
  • 资助金额:
    $ 28.38万
  • 项目类别:
Targeting Prolyl Peptidases in Tamoxifen Resistant Breast Cancer
靶向脯氨酰肽酶治疗他莫昔芬耐药乳腺癌
  • 批准号:
    9461165
  • 财政年份:
    2017
  • 资助金额:
    $ 28.38万
  • 项目类别:
Targeting Prolyl Peptidases in Tamoxifen Resistant Breast Cancer
靶向脯氨酰肽酶治疗他莫昔芬耐药乳腺癌
  • 批准号:
    9115348
  • 财政年份:
    2016
  • 资助金额:
    $ 28.38万
  • 项目类别:
Targeting Prolyl Peptidases in Tamoxifen Resistant Breast Cancer
靶向脯氨酰肽酶治疗他莫昔芬耐药乳腺癌
  • 批准号:
    9253372
  • 财政年份:
    2016
  • 资助金额:
    $ 28.38万
  • 项目类别:
Targeting Prolyl Peptidases in Tamoxifen Resistant Breast Cancer
靶向脯氨酰肽酶治疗他莫昔芬耐药乳腺癌
  • 批准号:
    9912119
  • 财政年份:
    2016
  • 资助金额:
    $ 28.38万
  • 项目类别:
Identification and Targeting Therapy Resistant Osteosarcoma
骨肉瘤耐药性的识别和靶向治疗
  • 批准号:
    8814732
  • 财政年份:
    2015
  • 资助金额:
    $ 28.38万
  • 项目类别:
Modeling The Etiology of P53 Mutated Cancer Cells
P53 突变癌细胞的病因学建模
  • 批准号:
    8571884
  • 财政年份:
    2013
  • 资助金额:
    $ 28.38万
  • 项目类别:
Modeling The Etiology of P53 Mutated Cancer Cells
P53 突变癌细胞的病因学建模
  • 批准号:
    8704904
  • 财政年份:
    2013
  • 资助金额:
    $ 28.38万
  • 项目类别:
Cellular Responses to p53 Activation by Nutlin-3a
Nutlin-3a 激活 p53 的细胞反应
  • 批准号:
    7735485
  • 财政年份:
    2009
  • 资助金额:
    $ 28.38万
  • 项目类别:
Cellular Responses to p53 Activation by Nutlin-3a
Nutlin-3a 激活 p53 的细胞反应
  • 批准号:
    8271293
  • 财政年份:
    2009
  • 资助金额:
    $ 28.38万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 28.38万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 28.38万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 28.38万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 28.38万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 28.38万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 28.38万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 28.38万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 28.38万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 28.38万
  • 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
  • 批准号:
    RGPIN-2018-04753
  • 财政年份:
    2022
  • 资助金额:
    $ 28.38万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了